Published: 22 October 2014
Author(s): Yang Xiang-hui, Xiao Lang, Zhang Yan, Zhang Li, Shi Xiao-feng, Ren Hong
Section: Original Article

Current results had demonstrated lamivudine (LAM) contributed to improve liver function and short-term prognosis in patients with hepatitis B virus-related acute-on-chronic liver failure (ACLF), but data concerning the outcome of long-term prognosis are limited. Our objective was to explore the prediction value of early viral response for prognosis and LAM resistance in ACLF patients with lamivudine treatment within 96weeks.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.